---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-016916"
form_type: "8-K"
ticker: "TTRX"
cik: "0002023016"
company_name: "Turn Therapeutics Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:34:46.025345+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Turn Therapeutics appoints former CDC Director Dr. Robert Redfield as Senior Advisor for GX-03

## Summary
- Dr. Redfield appointed Senior Advisor of Health Policy and Regulatory Affairs, effective immediately.
- He will provide strategic guidance on clinical development and regulatory positioning of lead candidate GX-03.
- GX-03 is currently in Phase 2 clinical trials for dermatologic inflammatory conditions.
- Dr. Redfield served as 18th Director of the CDC (2018-2021) and led federal public health responses.
- Turn Therapeutics is a clinical-stage biotech focused on targeted inflammatory and immunology therapies.

## SEC filing metadata
- accession: 0001213900-26-016916
- form_type: 8-K
- ticker: TTRX
- cik: 0002023016
- company_name: Turn Therapeutics Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023016/000121390026016916/0001213900-26-016916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023016/000121390026016916/ea0277212-8k_turn.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-016916
- JSON: https://secwatch.observer/filing/0001213900-26-016916.json
- Plain text: https://secwatch.observer/filing/0001213900-26-016916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.